| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| ovoveil | ||||||||
| Medilab Corporation | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Established the Farma Foods Research Institute in Kume, Kume-gun, Kyoto Prefecture, with a capital of 10,000 thousand yen, for the purpose of developing and selling functional food ingredients, etc.
Established: September 12, 1997.
Established.
Relocated headquarters to Shimogyo-ku, Kyoto City.
Relocated headquarters to Minami-ku, Kyoto City.
Released Helicobacter pylori chicken egg antibody 'OboProN®'.
Released GABA-containing ingredient 'Farma GABA®'.
Released catechin ingredient 'Farma Foods Delicious Catechin™'.
Changed company name to Farma Foods Inc.
Established Keihan Research Institute in Kizu Town, Kyoto Prefecture as a development base for the biomedical division.
Listed shares on the Tokyo Stock Exchange Mothers.
Relocated headquarters to Nishi-ku, Kyoto City.
Released egg white peptide 'RanPep®'.
Established Hiroshima Biomedical Co., Ltd. (49% ownership) to pursue research and development in blood purification therapy using chicken egg antibodies and to expand into diagnostic reagents and reagents.
Established the LSI Business Division to promote contract research services in the LSI sector.
Launched folic acid egg business in China.
Started direct sales business.
Released hyaluronic acid production promoter 'iHA®' and invested in Benart Co., Ltd. (33.3% ownership).
Launched direct sales business 'Tamago Base' and released supplement 'Tamago Samin®' containing iHA®.
Acquired a portion of shares of Benart Co., Ltd., resulting in a 50% ownership stake.
Opened an in-house call center for the mail-order business "Tamago Base" in Chuo-ku, Fukuoka City.
Obtained ISO 9001 certification for the quality management system.
Established "Farma Foods Communication Co., Ltd.", which handles call center operations for the mail-order business "Tamago Base" (our ownership stake: 75%).
In the biomedicine business, began joint research with the National Cancer Center (a national research and development institution) on the development of monoclonal antibody drugs for malignant tumor treatment.
Acquired shares of Future Lab Co., Ltd., making it a subsidiary.
Changed listing to the Second Section of the Tokyo Stock Exchange.
Received the 2018 Japan Society of Agricultural and Biological Chemistry "Agricultural and Biological Chemistry Technology Award" (for establishing GABA production technology and developing high-function foods).
Won the Gold Award at the Wellness Food Japan Award 2018 for "Tamago Samin® EX".
In the biomedicine business, entered into a joint research agreement with Tanabe Pharma Corp. (formerly Tanabe Mitsubishi Pharma Corp.) on antibody therapeutics aimed at treating autoimmune diseases.
Launched the quasi-drug "Neumo®" containing HGP®.
Acquired all shares of consolidated subsidiary Farma Foods Communication Co., Ltd., making it a wholly-owned subsidiary.
Designated to the First Section of the Tokyo Stock Exchange.
Designated to the First Section of the Tokyo Stock Exchange.
Acquired shares of Meiji Pharmaceutical Co., Ltd. to expand the functional materials and mail-order businesses, making it a subsidiary (100% ownership, now a consolidated subsidiary).
Grouped Tokushima Applus Science to strengthen the exploration and identification of drug discovery targets.
Invested in Onkyō Co., Ltd. to strengthen sales of health and medical devices and AI-based target discovery in drug development, making it an associate company (36.3% ownership, currently an equity-method affiliate).
Acquired shares of Sosei CVC Co., Ltd. (now PF Capital Co., Ltd.) to strengthen synergy with the biomedicine business, making it a subsidiary.
On TV Asahi's program "Shiawase no Tane.," the new fiber "ovoveil®" born from eggs is scheduled to be introduced on November 14, 2026. The focus will be on the eggshell membrane, combining it with plant-based ingredients to develop technology for use in clothing, and highlighting initiatives that create new value from unused resources.
The article published in the Chemical Industry Daily Report introduced the overview of the new mid-term management plan "SPRING 1K" formulated by Pharma Foods Inc., as well as the sales and profit targets for the fiscal year ending July 2029. The article focuses on strengthening existing businesses and exploring new business areas, including expanding the sale of over-the-counter pharmaceuticals in the pharmaceutical business, promoting drug discovery, and overseas expansion of the egg shell membrane-derived fiber "ovoveil."
Pharma Foods announced that the full share acquisition procedures of Marine Profoods Co., Ltd. were completed on October 30, 2026. The company plans to engage in the planning, development, and sale of agricultural, livestock, and aquaculture products, as well as soybean processed goods. The impact of this transaction on performance is under review, and any matters that need to be disclosed will be promptly released.
Farma Foods Inc. conducted a luncheon seminar at ICPH & ICoFF 2026 and presented three new findings on FarmaGABA® and Ceramino®. The presentation also shared research results on discovering unknown functional peptides hidden in food. Moving forward, the company aims to enhance the value of existing materials and create new business opportunities, accelerating its expansion into global markets.
Farma Foods Inc. reported the business report and consolidated financial statements for the period from August 1, 2025 to July 31, 2026 at the 29th regular shareholders' meeting held on October 28, 2026. Additionally, a final dividend of ¥12.5 per share was approved for the distribution of surplus funds, setting the annual dividend at ¥25. The appointment of 10 directors was also approved.
Farma Foods Inc. submitted its 29th term Securities Report covering the period from August 1, 2025 to July 31, 2026, on October 23, 2026. The report includes basic information such as company name, president, head office location, telephone number, and contact person.
Pharma Foods Inc. and MP Gokyo Food & Chemical conducted a human clinical trial of the functional material 'TamariNoil™' derived from tamarind peel, confirming that the group taking 200 mg daily for four weeks had a significantly lower abdominal visceral fat area compared to the placebo group. Additionally, exploratory analysis targeting visceral fat-type obesity showed significant reductions in weight, BMI, waist circumference, and body fat mass, and the results were published in the Journal of Food Bioactives.
Pharma Foods confirmed in a human clinical trial that the temporary facial puffiness sensation is significantly reduced by continuous consumption of the egg white-derived material 'Runpep®'. The research findings were published in the international journal 'Journal of Food Bioactives'. The company aims to advance functional research and expand into functional foods and beauty-related foods.
Pharma Foods Inc. announced on October 16, 2026, at a board meeting that it had formulated the 2029 Medium-Term Management Plan '1K Project - SPRING Strategy', covering a three-year period from July 2027 to July 2029. The basic policy is to leverage its proprietary biotechnologies and R&D capabilities to strengthen the profitability of existing businesses and drive the development of new growth areas, emphasizing profit growth and cash generation capability. The growth scenario outlines a plan to move from foundational building to a leap forward.
On October 13-14, 2026, Farmfoods Co., Ltd., which debuted at PERFORMANCE DAYS MUNICH in Munich, Germany, announced the knit fabric 'OVO/CAS PL KNIT' made with eggshell membrane-derived fiber 'ovoveil®'. This fabric received the 'Cellulose Award', which evaluates material development for cellulose-based fibers, and was highly praised among 599 suppliers that exhibited.